# Meditrina

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/meditrina

- Industry: Medical Devices & Equipment
- Headquarters: Cupertino, US
- Website: www.avetasystem.com
- Total disclosed funding: $23M
- Latest round: Series C (Jun 2, 2020)
- Investors on record: 3

## About

Meditrina, Inc. is a medical technology company that develops the Aveta® System, a comprehensive solution for intrauterine tissue removal, improving the efficacy and comfort of hysteroscopic procedures.Founded in 2016 in Cupertino, US, Meditrina, Inc. specializes in advanced intrauterine medical devices. The company secured a total of USD 10.00 mn in funding during its SERIES C round on June 2, 2020, led by Deerfield Management. The total amount raised to date is USD 10.00 mn, with a current company valuation of USD 70.31 mn. John Shadduck is the founder of the company.Meditrina, Inc. specializes in the Aveta® System, an innovative all-in-one tissue removal solution designed for intrauterine pathology. This system incorporates advanced features such as integrated camera rotation, automatic upright image orientation lock, and an advanced fluid management system, enhancing the efficiency and comfort of hysteroscopic procedures. The Aveta® System boasts the smallest insertion diameter and the largest working channel among single-use hysteroscopes, optimizing tissue resection while prioritizing patient comfort. Targeting healthcare providers, including gynecological clinics and hospital operating rooms, the product facilitates procedures such as fibroid removal, polypectomy, and diagnostic and therapeutic hysteroscopy. Meditrina markets the Aveta® System primarily in the United States and internationally, offering versatile solutions for varied surgical settings.Revenue generation for Meditrina, Inc. is driven by the sale of its Aveta® System and associated single-use medical devices. The company operates on a B2B model, selling directly to healthcare facilities which require advanced hysteroscopic solutions. Transactions typically involve bulk orders and procurement contracts, ensuring a consistent supply of the Aveta® System and its components. Pricing strategies reflect the premium nature of the innovative technology, catering to hospitals and outpatient facilities. As a trademarked product, the Aveta® System is positioned to capture a significant market share in the intrauterine procedure space, with ongoing engagements to further expand its presence among healthcare providers.In June 2020, Meditrina, Inc. raised USD 10.00 mn in venture funding, part of a larger USD 20.00 mn equity financing round led by Deerfield Management. The funding will support the development of upcoming products designed for enhanced intrauterine procedures. Meditrina plans to expand into new international markets, although specific regions have not been disclosed at this time. The company aims to leverage its recent funding to strengthen its market presence and enhance product offerings.

## Funding rounds

- Series C, Jun 2, 2020, $10M — Deerfield Management
- Series B, Dec 18, 2019, $13M — ShangBay Capital, Aethan Capital, Inc.

## Investors

- ShangBay Capital (https://capitalatlas.ai/funds/shangbay-capital) — Series B
- Aethan Capital, Inc. — Series B
- Deerfield Management (https://capitalatlas.ai/funds/deerfield-management) — Series C